CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas. Show more
2100 West Loop South, Houston, TX, 77027, United States
Market Cap
1.299M
52 Wk Range
$2.06 - $34.80
Previous Close
$2.28
Open
$2.29
Volume
12,395
Day Range
$2.15 - $2.29
Enterprise Value
-5.471M
Cash
7.201M
Avg Qtr Burn
-3.052M
Insider Ownership
0.16%
Institutional Own.
24.90%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|